Pfizer and the White House announced a drug pricing agreement featuring a direct-to-consumer platform named TrumpRX, aimed at lowering U.S. drug costs by offering medications at average discounts of 50% or more compared to list prices. This initiative, part of President Trump's Most Favored Nation strategy, targets government programs and out-of-pocket consumers but excludes commercial insurance holders. Details remain scarce on the exact drugs covered and beneficiary populations, while recent tariff threats and delays have complicated industry dynamics. The move signals an attempt to balance domestic drug pricing pressures with pharmaceutical innovation.